Managed Healthcare Executive December 8, 2023
Denise Myshko

The FDA has approved Lyfgenia and Casgevy to treat patients with sickle cell disease. Casgevy is the first FDA-approved gene therapy to use the CRISPR gene editing technology.

The FDA has approved two gene therapies to treat patients with patients 12 years and older with severe sickle cell disease.

Vertex Pharmaceuticals’ gene therapy Casgevy (exagamglogene autotemcel) is the first gene therapy approval by the FDA that uses the CRISPR/Cas9 technology. Casgevy is a one-time gene therapy that uses a patient’s own hematopoietic stem cells that are edited to produce high levels of fetal hemoglobin in red blood cells. Patients receiving this therapy have stem cells extracted and then edited using the CRISPR/Cas9 technology. The edited stem cells are then infused...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article